XML 24 R24.htm IDEA: XBRL DOCUMENT
v3.2.0.727

Collaborative and Other Agreements (Details) $ in Thousands, € in Millions | 3 Months Ended | 6 Months Ended
--- | --- | ---
Jun. 30, 2015 USD ($) | Jun. 30, 2014 USD ($) | Jun. 30, 2015 USD ($) | Jun. 30, 2015 EUR (€) | Jun. 30, 2014 USD ($)
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |
Licensing and collaboration agreement revenue | $ | $ 945 | $ 1,201 | $ 1,207 |  | $ 2,164
Royalties paid, minimum (in hundredths) |  |  | 0.50% | 0.50% |
Royalties paid, maximum (in hundredths) |  |  | 5.00% | 5.00% |
Collaborative Arrangement [Member] |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |
Eligible milestone payments receivable |  |  |  | € 356.5 |
Eligible milestone payments receivable under specific rights not met |  |  |  | 633.8 |
Eligible milestone payments receivable, after amendment |  |  |  | 341.5 |
Eligible milestone payments receivable under specific rights not met, after amendment |  |  |  | € 618.8 |
Collaborative Arrangement [Member] | Servier Loan [Member] |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |
Future initial research and development expenses to be funded by counterparty | $ |  |  | $ 50,000 |  |
Licensing and collaboration agreement revenue | $ | $ 300 | $ 1,100 | $ 900 |  | $ 2,000
Collaborative Arrangement [Member] | Symplmed Pharmaceuticals [Member] |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |
Royalties paid, minimum (in hundredths) |  |  | 3.00% | 3.00% |
Royalties paid, maximum (in hundredths) |  |  | 10.00% | 10.00% |

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Revenue from multiple-deliverable arrangements that include licensing fees and services revenue. Licensing revenue is consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity. Services revenue may be derived by providing other, nonspecified, services during the reporting period. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1(d),(e)) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 1 -Article 5 + Details
Name: | us-gaap_LicenseAndServicesRevenue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Represents the eligible milestone payments receivable. + References No definition available. + Details
Name: | xoma_EligibleMilestonePaymentsReceivable
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Represents eligible milestone payments receivable after amendments. + References No definition available. + Details
Name: | xoma_EligibleMilestonePaymentsReceivableAfterAmendments
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Represents eligible milestone payments receivable under specific rights not met. + References No definition available. + Details
Name: | xoma_EligibleMilestonePaymentsReceivableUnderSpecificRightsNotMet
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Represents Eligible milestone payments receivable under specific rights not met after amendment. + References No definition available. + Details
Name: | xoma_EligibleMilestonePaymentsReceivableUnderSpecificRightsNotMetAfterAmendment
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The aggregate amount of future initial clinical research and development expenses that will be funded by the counterparty under a collaborative arrangements. + References No definition available. + Details
Name: | xoma_FutureInitialResearchAndDevelopmentExpensesToBeFundedByCounterpartyUnderCollaborativeArrangement
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The maximum percentage of royalties paid to selling price of licensed components. + References No definition available. + Details
Name: | xoma_RoyaltiesPaidPercentageMaximum
Namespace Prefix: | xoma_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition The minimum percentage of royalties paid to selling price of licensed components. + References No definition available. + Details
Name: | xoma_RoyaltiesPaidPercentageMinimum
Namespace Prefix: | xoma_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_DeferredRevenueArrangementTypeAxis=xoma_ServierLoanMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_DeferredRevenueArrangementTypeAxis=xoma_SymplmedPharmaceuticalsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |